Molecular Formula | C13H14N6O |
Molar Mass | 270.29 |
Density | 1.397±0.06 g/cm3(Predicted) |
Boling Point | 605.0±65.0 °C(Predicted) |
Solubility | DMSO: 16 mg/mL |
pKa | 12.54±0.10(Predicted) |
Storage Condition | -20℃ |
In vitro study | XL765 was the first oral dual inhibitor of PI3K and mTOR, with IC50 values of 39, 113, 9, 43, and -150 nM for p110α, β, γ, δ, and mTOR, respectively. In vitro, XL765 reduced cell viability in a concentration-dependent manner. |
In vivo study | Oral feeding of XL765 resulted in a 12-fold decrease in metaphase tumors compared to the control group. XL765 showed activity either alone or in combination with other drugs in various GBM xenografts. XL765 acts on in vitro cultured human xenografts, resulting in down-regulation of the downstream phosphorylated proteins of PI3K: pAkt and pPRAS40, and the downstream phosphorylated proteins of mTOR: pS6 and p4EBP1. |
HS Code | 29337900 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.7 ml | 18.499 ml | 36.997 ml |
5 mM | 0.74 ml | 3.7 ml | 7.399 ml |
10 mM | 0.37 ml | 1.85 ml | 3.7 ml |
5 mM | 0.074 ml | 0.37 ml | 0.74 ml |